A new study suggests increasingly popular GLP-1 drugs could help cut opioid and alcohol abuse nearly in half.
New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.
Obesity drugmaker Rivus is working with banks to complete a US public listing that could happen before the end of the year.